Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-050119
Filing Date
2025-05-16
Accepted
2025-05-16 18:28:02
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 18244
  Complete submission text file 0001104659-25-050119.txt   20011
Mailing Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320
Business Address 1280 RANCHO CONEJO BLVD THOUSAND OAKS CA 91320 805-623-4211
Atara Biotherapeutics, Inc. (Subject) CIK: 0001604464 (see all company filings)

EIN.: 460920988 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-88393 | Film No.: 25961048
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 30 GREYLOCK ROAD WELLESLEY MA 02481
Business Address 30 GREYLOCK ROAD WELLESLEY MA 02481 781-235-7974
Adiumentum Capital Fund I LP (Filed by) CIK: 0002023734 (see all company filings)

EIN.: 992041819 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A